A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: Results from long-term follow-up

Breast Cancer

Volumn 20, Issue 4, 2013, Pages 357-362

  Julka, Pramod K ^a   Chacko, Raju T ^b   Nag, Shona ^c   Parshad, Rajinder ^a   Nair, Aravindan ^b   Koppiker, Chaitanyanand B ^c   Xue, Fen Chao Richard ^d   Barraclough, Helen ^e   Dhindsa, Navreet ^f   Seth, Anil ^g   Majumdar, Anurita ^g   Puri, Tarun ^g  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b CHRISTIAN MEDICAL COLLEGE   (India)

^c JEHANGIR HOSPITAL   (India)

^d Eli Lilly China   (China)

^e ELI LILLY AUSTRALIA PTY LTD   (Australia)

^f MERRIMACK PHARMACEUTICALS   (United States)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

Breast cancer; Cisplatin; Doxorubicin; Gemcitabine; Neoadjuvant

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CARCINOMA; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER STAGING; DIARRHEA; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENETIC MARKER; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOLOGY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84892787398     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-012-0343-4     Document Type: Article

References (20)

1. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940-9.
2. Van Moorsel CJA, Peters GJ, Pinedo HM. Gemcitabine: future prospects of single-agent and combination studies. Oncologist. 1997;2:127-34.
3. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol. 1995;13:2731-6.
4. Spielmann M, Lombart-Cussac A, Kalla S, Espié M, Namer M, Ferrero JM, et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology. 2001;60:303-7.
5. Blackstein M, Vogel CL, Ambinder J, Cowan J, Pearce P, Iglesias J, et al. Phase II study of gemcitabine in metastatic breast cancer. Proc Am Soc Clin Oncol. 1996;15:117. Abstract 135.
6. Sanchez-Rovira P, Jaen A, Duenas R, Porras I, Martínez E, Medina B, et al. Neoadjuvant gemcitabine therapy for breast cancer. Clin Breast Cancer. 2002;3(Suppl 1):S39-44.
7. Perez-Manga G, Lluch A, Alba E, Moreno-Nogueira JA, Palomero M, García-Conde J, et al. Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. J Clin Oncol. 2000;18:2545-52.
8. Gomez H, Kahatt C, Falcon S, Santillana S, de Mendoza FH, Valdivia S, et al. A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIB breast cancer: a preliminary report. Semin Oncol. 2001;28(Suppl 10):57-61.
9. Silva A, Gonzalez H, Perez M, Rivera S, Lira-Puerto V, Castaneda N, et al. Neoadjuvant gemcitabine plus epirubicin in locally advanced breast cancer: evidence of activity in a phase II study. Proc Am Soc Clin Oncol. 2002;21:2015. Abstract.
10. Silva JA, Perez M, Rivera S, Olivares G, Lira-Puerto V, Castañeda N, et al. Phase II study of neo-adjuvant gemcitabine plus epirubicin in primarily unresectable locally advanced breast cancer. Breast J. 2008;14:397-8.
11. Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol. 2000;18:2245-9.
12. Kim JH, Oh SY, Kwon H-C, Lee S, Kim SH, Kim DC, et al. Phase II study of gemcitabine plus cisplatin in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Cancer Res Treat. 2008;40:101-5.
13. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12:320-7.
14. Julka PK, Chacko RT, Nag S, Parshad R, Nair A, Oh DS, et al. A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. Br J Cancer. 2008;98:1327-35.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
16. Cox DR. Regression models and life tables. J Royal Stat Soc (Ser B). 1972;34:187-220.
17. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992;10:239-53.
18. Yardley DA, Peacock NW, Dickson NR, White MB, Vázquez ER, Foust JT, et al. A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer. Clin Breast Cancer. 2010;10:217-23.
19. Yerushalmi R, Hayes MM, Gelmon KA, Chia S, Bajdik C, Norris B, et al. A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers. Clin Breast Cancer. 2009;9:166-72.
20. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26:778-85.